Clinical Trial Search

Primary: Change in Premenstrual Symptoms as Measured by the Premenstrual Tension Scale (PMTS) — -6.9; -5.5; -5.5; -8.3 score on a scale — p== 0.57

Primary: Linear Ground Reaction Force Loading Rate — 0.276; -0.146; -0.135 multiples of body weight per second

Primary: Average Pain Intensity Numerical Rating Scale (PI-NRS) Score - From 0 to 4 Hours Post-dose — 2.08; 2.73; 1.95; 2.04 Units on a scale

Primary: Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment — 2; 2 score on a scale

Primary: Vitamin D Status; VDR Status — 13.81; 17.49 ng/ml

Primary: Day 7 Atazanavir Oral Clearance — .25; .18 L/h/kg

Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE) — 69.2; 83.3; 100.0; 66.7 percentage of participants

Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 18.4; 35.6; 48.1; 51.8 percentage of participants…

Primary: Cell-associated HIV DNA — 35; 43; 81; 16 nucleic acid copies per million cells

Primary: Overall Survival (OS) — 11.8; 15.7; 13.1 months — p=0.8253

Primary: Cohort 1: Percent Change From Baseline in Plasma Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours (AUC0-4h) by Mixed-meal Tolerance Test (MMTT) to…

Primary: Viral Shedding — 8; 4; 7; 4 Participants

Primary: Number of Patients Virologically Suppressed (HIV RNA <50 Copies/ml) at 48 Weeks. — 5 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 68; 90; 20; 32 participants

Primary: Total Hydromorphone Use — 161.5; 159.6; 195.9; 41.9 mcg/Kg